There have been nine clinical studies involving 1,155 symptomatic patients using SureTouch technology in the U.S., China, and UK. Meta-analysis of these studies, using pathology as the gold standard, was performed. All studies included in this meta-analysis were on symptomatic patients. To identify the presence of an abnormality, the sensitivity of SureTouch to detect breast masses was 89% in comparison with CBE which was 83%.

To identify the presence of breast cancer, the sensitivity of SureTouch in detecting breast cancer was 85%, in comparison to CBE (59%), mammography (76%) and ultrasound (90%) ,the specificity of SureTouch in detecting breast cancer was 79% in comparison to CBE (78%), mammography (71%) and ultrasound (79%), and the accuracy of SureTouch in detecting breast cancer was 82% comparison with CBE (67%), mammography (74%) and ultrasound (84%). The following table summarizes this information.

Breast Cancer Detection Summary on Symptomatic Patients

Tactile Imaging Mammogram Ultrasound
Sensitivity for Cancer Detection 85 76 90
Specificity for Cancer Detection 79 71 79
Accuracy for Cancer Detection 82 74 84
 

The graph bellow summarizes the specificity and sensitivity in identifying breast cancer from six of these studies, all using pathology as gold standard.

 

The conclusion, according to this meta-analysis, is that SureTouch is not only sensitive in the detection of breast masses, but it also identifies breast cancer with comparable or greater sensitivity and specificity compared with other standard imaging modalities, while remaining cost effective.